MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Narazaciclib

CAS No. : 1357470-29-1

MCE 站：Narazaciclib

产品活性：Narazaciclib (ON123300) 是一种强效的，可透过血脑屏障的多激酶抑制剂，可抑制 CDK4 (IC₅₀=3.9 nM），Ark5 (IC₅₀=5 nM)，PDGFRβ (IC₅₀=26 nM)，FGFR1 (IC₅₀=26 nM)，RET (IC₅₀=9.2 nM) 和 FYN (IC₅₀=11 nM)。Narazaciclib 在脑肿瘤中抑制 Akt 磷酸化及激活 Erk。Narazaciclib 抑制 CDK6，IC₅₀ 为 9.82 nM。

研究领域：Cell Cycle/DNA Damage  |  PI3K/Akt/mTOR  |  Epigenetics  |  Protein Tyrosine Kinase/RTK

作用靶点：CDK  |  AMPK  |  PDGFR

In Vitro: Narazaciclib (ON123300) inhibits U87 glioma cell proliferation with an IC₅₀ of 3.4±0.1 μM.?Narazaciclib (1 ａnd 10 μM) inhibits cell proliferation in a panel of 11 glioma models including a patient-derived model (GBM10).
?Narazaciclib (6.3 μM; 1 h) reduces phosphorylation of Akt ａnd its downstream signaling components, P70S6K, 40S rpS6 ａnd Rb S780, yet ON123300 induces Erk activation in U87 cells; both in a dose- ａnd time-dependent manner.?ON123300 inhibits PI3Kδ with the IC₅₀ of 144nM.

In Vivo: Narazaciclib (ON123300) decreases p-Akt expression ａnd increases p-Erk activity in brain tumors upon administration at both IV doses of 5 mg/kg ａnd 25 mg/kg in U87 brain tumor-bearing mouse. The half-life (T_1/2) is 1.5 h for 5 mg/kg ａnd 25 mg/kg in plasma.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  CNS-Penetrant Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antioxidant Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Angiogenesis-Related Compound Library  |  Lipid Metabolism Compound Library   |  Glucose Metabolism Compound Library  |  Cancer Stem Cells Compound Library  |  Heterocyclic Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Serine/Threonine Kinase Inhibitor Library  |  SY-5609  |  CLK1/2-IN-1  |  Sennoside B  |  MFH290  |  SB-218078  |  Toyocamycin  |  (S)-LY3177833 hydrate  |  Dinaciclib  |  EGFR/HER2/CDK9-IN-2  |  CDK8-IN-11  |  SNS-032  |  M2N12  |  Palbociclib-d₈  |  EGFR/CDK2-IN-1  |  BSJ-04-132  |  (E/Z)-Zotiraciclib  |  CCT-251921  |  BS-181  |  Flumatinib mesylate  |  Ribociclib-d₈  |  CDK9-IN-9  |  Flavopiridol  |  ZLN024  |  Multi-kinase-IN-2  |  SRI-29329  |  YLF-466D  |  dCeMM4  |  GSK 3 Inhibitor IX  |  CDK9-IN-7  |  PROTAC CDK9 degrader-8

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。